Baricitinib Medicine 09 January 2018 Extended indication Psoriasis (wg); Conditioneel exzeem (wg); Graft vs Host Disease (clinicaltrials.gov); Arteritis, Giant Cell (clinicaltrials.gov) Therapeutic value No judgement Total cost Registration phase Unknown Product Active substance Baricitinib Domain Chronic immune diseases Reason of inclusion Main indication Skin diseases Extended indication Psoriasis (wg); Conditioneel exzeem (wg); Graft vs Host Disease (clinicaltrials.gov); Arteritis, Giant Cell (clinicaltrials.gov) Current proprietary name Already available biosimilars / generics Proprietary name Olumiant Manufacturer Eli Lilly Portfolio holder Mechanism of action Unknown Route of administration Oral Therapeutical formulation Tablet Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date Expected Registration Orphan drug No Registration phase Unknown Reimbursement Medicine sluice Additional remarks Indicatie-uitbreiding Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a day Dosage per administration 4 mg References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost € 14,000.00 - 15,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Medicijnkosten.nl Additional remarks Huidige prijs per 4mg tablet € 38,85. € 14.178,50 pppj Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions No Indication extensions References Additional remarks Fabrikant (nov 2017): indicatie uitbreidingen worden niet verwacht binnen de komende 2 jaar. Other information Additional remarks